Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block may curb ICU delirium in seniors

NCT ID NCT07558642

Symptom relief Sponsor: Antalya Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether a stellate ganglion block (a nerve injection) can reduce delirium (sudden confusion) and improve sleep-wake cycles in intensive care patients aged 65 and older. Delirium is common in the ICU and linked to worse outcomes. The trial will compare 130 patients who receive the block with those who do not, measuring confusion levels and blood markers of circadian rhythm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 65 years or older expected to remain in the intensive care unit for more than 48 hours * RASS score \> -4 Exclusion Criteria: * History of neurodegenerative disease (e.g., Alzheimer's disease, dementia, vascular dementia) * Uncontrolled psychiatric disorders * Alcohol use disorder and/or substance abuse * History of traumatic brain injury or ischemic/hemorrhagic cerebrovascular event * Severe hearing and/or visual impairment * Benzodiazepine use * Renal failure (Acute Kidney Injury stage 2-3) and/or liver failure * Beta-blocker use * Contraindications to stellate ganglion block (e.g., coagulopathy, glaucoma, recent myocardial infarction) * Sepsis * Allergy to bupivacaine * Inability to communicate in Turkish or English * Severe hyponatremia * Hemodynamic instability

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stellate ganglion block are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

delirium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stellate ganglion block

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Antalya Training and Research Hospital

    Antalya, Muratpaşa, 07100, Turkey (Türkiye)

  • Antalya Training and Research Hospital

    Antalya, Muratpaşa, 07100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.